Denodo Adds to Executive Team with Key Appointments: Daniel Lender Joins as Chief Financial Officer and Stephen Welles as Chief Legal Officer
10.11.2022 11:00:00 EET | Business Wire | Press release
Denodo, a leader in data management, today announced two key additions to its executive team to help to guide Denodo through its next phase of growth: Daniel Lender as Chief Financial Officer and Stephen Welles as Chief Legal Officer. Mr. Lender and Mr. Welles will lead all of Denodo’s global financial and legal strategy and operations, reporting directly to Denodo’s Chief Executive Officer, Angel Viña.
“We’re excited to welcome Daniel as our new CFO and Stephen as our new CLO,” said Angel Viña, CEO and Founder of Denodo. “Daniel brings extensive financial and operational experience in enterprise software to our executive team and Stephen adds his broad and deep expertise in legal matters. These two key appointments strengthen our executive team and will be a great asset to Denodo as we continue to grow our global business.”
Daniel Lender is the newest addition to Denodo’s executive leadership team and brings more than 30 years of enterprise software and financial markets experience to his role. Mr. Lender joins Denodo after a long tenure with QAD Inc., a leading provider of next generation manufacturing and supply chain management solutions in the cloud, where he served as executive vice president and chief financial officer.
“I am absolutely thrilled to join Denodo at this stage,” said Daniel Lender. “With data growing at an exponential rate and multi-cloud platforms becoming the norm, I believe Denodo, with its unique and proprietary platform, is well positioned to continue its growth path and help its customers unlock value from their data. I look forward to working with the Denodo leadership team to help fuel Denodo’s next phase of growth.”
Stephen Welles brings more than 25 years of experience to his new position as Chief Legal Officer. He joined Denodo from Wilson Sonsini Goodrich & Rosati, the premier legal advisor to technology, life sciences, and other growth enterprises worldwide, where he was a senior counsel. Before that, he was the senior vice president and general counsel at Oplink Communications, an optical networking equipment company with more than 3,000 employees worldwide.
“Denodo has a bright future and I am excited to be a part of the team,” said Stephen Welles. “Denodo’s mission to help enterprises become data-driven organizations is an important one, and it will continue to drive Denodo’s growth.”
Denodo was recognized as a Leader in the 2022 Gartner® Magic Quadrant™ for Data Integration Tools for a third year in a row, and in the Forrester Wave™: Enterprise Data Fabric, Q2 2022 for a second year in a row. Denodo is the fastest growing vendor among the top 10 data integration vendors according to Gartner Market Share Analysis: Data Integration Software, Worldwide, 2021. Denodo also has been consistently receiving Customers’ Choice distinction in the Gartner Peer Insights 'Voice of the Customer': Data Integration Tools report for the last two years, showcasing how positively Denodo customers perceive the value of the product, services and support offered by Denodo.
Please tweet: News: @denodo adds to executive team - Daniel Lender as Chief Financial Officer and Stephen Welles as Chief Legal Officer to drive next phase of growth for #datamanagement and #dataintegration leader
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading data integration, management, and delivery platform using a logical approach to enable self-service BI, data science, hybrid/multi-cloud data integration, and enterprise data services. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across large enterprises and mid-market companies in 30+ industries have received payback in less than 6 months. For more information, visit www.denodo.com or call +1 877 556 2531 (US) / +44 (0) 20 7869 8053 (UK) / +65 6950 7489 (Singapore).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005616/en/
Contact information
Chris McCoin or Richard Smith
McCoin & Smith Communications Inc.
508-429-5988 (Chris) or 978-433-3304 (Rick)
chris@mccoinsmith.com or rick@mccoinsmith.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release
LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
